A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Conditions: Non Small Cell Lung Cancer; Cancer Interventions: Drug: Venetoclax; Drug: Pembrolizumab Sponsor: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Research | Study